SCNI Stock Holds Nasdaq Compliance As Trading Volatility Spikes

Scinai Immunotherapeutics Ltd. stocks have been trading up by 41.38 percent amid heightened investor optimism following recent developments

Live Update At 08:32:32 EDT: On Tuesday, October 13, 2026 Scinai Immunotherapeutics Ltd. stock [NASDAQ: SCNI] is trending up by 41.38%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SCNI is trading like a classic small-cap biotech battleground. Over the recent daily chart, Scinai Immunotherapeutics slid from a closing high near $1.98 back toward the mid‑$1s, then down closer to $1.16. That’s a sharp retrace, but the important part for traders is that SCNI has stayed above the key $1.00 level needed for Nasdaq compliance.

The intraday 5‑minute action shows wild premarket swings, with SCNI ripping from around $1.13 to a high near $3.34 before fading back into the $1.60–$2.00 range. That tells traders two things: liquidity is there, and day traders are active. This kind of range is exactly what momentum traders look for, but it demands tight risk control.

More Breaking News

• FCHL Stock Draws Day Traders As Volatility Spikes
• BKYI Stock Rockets As Gulf Deal And FIDO Win Draw Traders
• DataMeds AI (MEDS) Stock Roars On Oncology And Telehealth Push
• NOK Stock Slumps As Repeated ADR Selloffs Hit Nokia

Fundamentally, Scinai Immunotherapeutics is tiny. Revenue is only about $1.31M, with an enterprise value around $7.83M and a price‑to‑sales ratio of roughly 1.22. Book value per share is about $1.83, while SCNI trades below that, hinting the market still discounts the story. Returns on equity and assets are deep in negative territory, reminding traders this is a high‑risk biotech focused on future potential, not current profits.

Why Traders Are Watching SCNI Now

SCNI just cleared a major psychological and structural hurdle: Nasdaq’s $1.00 minimum bid requirement. For weeks, Scinai Immunotherapeutics carried the cloud of a possible delisting. That kind of overhang often scares off many traders and can crush liquidity. With compliance now restored, that immediate risk is off the table, and the Nasdaq matter is officially closed.

The detail that matters is how SCNI got there. Scinai Immunotherapeutics didn’t just spike for a day; it held above $1.00 for 19 consecutive trading sessions. That kind of stretch suggests real, if fragile, market support. For active traders, sustained closes above a key line in the sand often signal a shift in sentiment and open the door for new breakout or mean‑reversion setups.

At the same time, SCNI is trying to build a narrative beyond simple survival. The company has highlighted continued progress in its NanoAb immunology programs and expansion of its CDMO operations. That tells traders Scinai Immunotherapeutics is not standing still while it fixes listing issues. Instead, SCNI is using the breathing room from Nasdaq compliance to keep building its biotech and services engine.

Combine that operational push with the intraday volatility we see on the tape, and SCNI becomes a name momentum traders will keep on screen. This is the kind of chart where a single news headline on NanoAb developments or a new CDMO contract can trigger another violent leg up — or a hard fade — in a very short window.

Conclusion

For traders, the SCNI story right now is all about risk removal plus volatility. Scinai Immunotherapeutics has taken Nasdaq delisting off the immediate worry list by regaining compliance with the $1.00 bid price rule. That stabilizes the playing field and lets traders focus more on price action and catalysts than on exchange survival.

Under the hood, Scinai Immunotherapeutics remains a small, loss‑making biotech with modest revenue and negative returns. The upside case revolves around execution in its NanoAb immunology pipeline and steady growth of its CDMO business. If SCNI can convert those efforts into stronger fundamentals, the current discount to book value may start to close. If not, the stock can quickly round‑trip any rallies, as recent intraday swings already show.

For the Tim Sykes‑style community, SCNI is a textbook lesson in playing speculative biotech. There is news, there is a clear technical line at $1.00, and there is plenty of range. As Tim Sykes likes to say, “The pattern is the pattern, but your risk control is everything.” As Tim Bohen, lead trainer with StocksToTrade says, “A consistent trading routine beats sporadic action every time. Show up daily, and you’ll start to see the patterns others miss.”. Traders studying Scinai Immunotherapeutics should treat it exactly that way — as a volatile educational case where careful planning, fast cutting of losses, and disciplined profit taking matter more than any single headline.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.